Cytokine-modulating_JJ
activity_NN
of_IN
tepoxalin_NN
,_,
a_DT
new_JJ
potential_JJ
antirheumatic_NN
._.

Tepoxalin_NN
is_VBZ
a_DT
new_JJ
dual_JJ
cyclooxygenase\/5-lipoxygenase_NN
anti-inflammatory_JJ
compound_NN
currently_RB
under_IN
clinical_JJ
investigation_NN
._.

It_PRP
has_VBZ
been_VBN
shown_VBN
to_TO
possess_VB
anti-inflammatory_JJ
activity_NN
in_IN
a_DT
variety_NN
of_IN
animal_JJ
models_NNS
and_CC
more_RBR
recently_RB
to_TO
inhibit_VB
IL-2_NN
induced_JJ
signal_NN
transduction_NN
._.

The_DT
current_JJ
study_NN
was_VBD
conducted_VBN
to_TO
evaluate_VB
the_DT
cytokine_NN
modulating_VBG
activity_NN
of_IN
tepoxalin_NN
and_CC
the_DT
role_NN
of_IN
iron_NN
in_IN
these_DT
effects_NNS
._.

In_IN
human_JJ
peripheral_JJ
blood_NN
mononuclear_JJ
cells_NNS
-LRB-_-LRB-
PBMC_NN
-RRB-_-RRB-
stimulated_VBN
with_IN
OKT3\/PMA_NN
,_,
tepoxalin_NN
inhibited_VBD
lymphocyte_NN
proliferation_NN
with_IN
an_DT
IC50_NN
of_IN
6_CD
microM_NN
._.

Additionally_RB
,_,
it_PRP
inhibited_VBD
the_DT
production_NN
of_IN
LTB4_NN
-LRB-_-LRB-
IC50_NN
=_JJ
0.5_CD
microM_NN
-RRB-_-RRB-
and_CC
the_DT
cytokines_NNS
IL-2_NN
,_,
IL-6_NN
and_CC
TNF_NN
alpha_NN
-LRB-_-LRB-
IC50_NN
=_JJ
10-12_JJ
microM_NN
-RRB-_-RRB-
._.

Cytotoxicity_NN
was_VBD
not_RB
demonstrated_VBN
at_IN
these_DT
concentrations_NNS
._.

Add-back_JJ
experiments_NNS
with_IN
either_CC
cytokines_NNS
-LRB-_-LRB-
IL-2_NN
or_CC
IL-6_NN
-RRB-_-RRB-
,_,
LTB4_NN
or_CC
conditioned_JJ
media_NNS
failed_VBD
to_TO
restore_VB
the_DT
proliferative_JJ
response_NN
in_IN
the_DT
presence_NN
of_IN
tepoxalin_NN
._.

However_RB
,_,
the_DT
concurrent_JJ
addition_NN
of_IN
iron_NN
-LRB-_-LRB-
in_IN
the_DT
form_NN
of_IN
ferrous_NN
or_CC
ferric_JJ
chloride_NN
and_CC
other_JJ
iron_NN
salts_NNS
-RRB-_-RRB-
reversed_VBD
the_DT
inhibition_NN
of_IN
proliferation_NN
caused_VBN
by_IN
tepoxalin_NN
._.

Tepoxalin_NN
also_RB
inhibits_VBZ
the_DT
activation_NN
of_IN
NF_NN
kappa_NN
B_NN
,_,
a_DT
transcription_NN
factor_NN
which_WDT
acts_VBZ
on_IN
several_JJ
cytokine_NN
genes_NNS
._.

Tepoxalin_NN
's_POS
effect_NN
on_IN
NF_NN
kappa_NN
B_NN
is_VBZ
also_RB
reversed_VBN
by_IN
the_DT
addition_NN
of_IN
iron_NN
salts_NNS
._.

These_DT
data_NNS
suggest_VBP
that_IN
the_DT
action_NN
of_IN
tepoxalin_NN
to_TO
inhibit_VB
proliferation_NN
in_IN
PBMC_NN
may_MD
be_VB
at_IN
least_JJS
in_IN
part_NN
due_JJ
to_TO
its_PRP$
ability_NN
to_TO
reduce_VB
the_DT
amount_NN
of_IN
available_JJ
iron_NN
resulting_VBG
in_IN
decreased_VBN
activation_NN
of_IN
NF_NN
kappa_NN
B_NN
and_CC
subsequent_JJ
inhibition_NN
of_IN
cytokine_NN
production_NN
._.

